✦ LIBER ✦

Neuroprotection by estrogen in animal models of ischemia and Parkinson's disease

✍ Scribed by Istvan Merchenthaler; Paul J. Shughrue

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 686 KB
Volume: 66
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.20056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Animal models of Parkinson's disease

✍ Ranjita Betarbet; Todd B. Sherer; J. Timothy Greenamyre 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Animal models are important tools in experimental medical science to better understand pathogenesis of human diseases. Once developed, these models can be exploited to test therapeutic approaches for treating functional disturbances observed in the disease of interest. On the basis of e

New animal models of Parkinson's disease

✍ Benjamin Dehay; Erwan Bezard 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

## Abstract ## Background: Parkinson's disease is a progressive neurodegenerative disorder mainly characterized by the loss of dopaminergic neurons from the substantia nigra pars compacta and the presence, in the affected brain regions, of protein inclusions named Lewy Bodies. Despite the fact tha

A tale on animal models of Parkinson's d

A tale on animal models of Parkinson's disease

✍ Erwan Bezard; Serge Przedborski 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract Parkinson's disease is a neurodegenerative disorder whose cardinal manifestations are due primarily to a profound deficit in brain dopamine. Since the 1980s, several therapeutic strategies have been discovered to treat the symptoms of this neurological disorder, but as of yet, none halt

Synergistic antidyskinetic effects of to

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease

✍ Christopher Kobylecki; Michael P. Hill; Alan R. Crossman; Paula Ravenscroft 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

## Abstract L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at __N__‐methyl‐D‐aspartate glutamate receptors. The antiepileptic drug topiramate, which blocks α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, has also been sh

Neuroprotective effects of (±)-kavain in

Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease

✍ Nicole Schmidt; Boris Ferger 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o

Neuroprotective effect of riluzole in a

Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence

✍ Maria C. Obinu; Michel Reibaud; Véronique Blanchard; Saliha Moussaoui; Assunta I 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

## Abstract Our study aimed to determine whether riluzole, which has shown efficacy as a disease‐modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective str